HCV drug from Gilead shows efficacy in late-stage trial

02/20/2013 | Yahoo

Patients with certain genotypes of hepatitis C who took Gilead Sciences' sofosbuvir in a late-stage clinical trial had cure rates of 50% at 12 weeks and 73% at 16 weeks, compared with the 25% historic cure rate among such patients. Sofosbuvir-treated patients with cirrhosis showed lower sustained virologic response, researchers said.

View Full Article in:

Yahoo

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President, Science and Regulatory Affairs
American Beverage Association
Washington, DC
Senior Manager of Medical Management
Network Health
Medford, MA
MEDICAL SCIENCE LIAISON - 14000002RO
Abbott
Columbus, OH
Manager, Medical Management
Network Health
Medford, MA
Medical Director - Cataract
Abbott
Santa Ana, CA